Publications by authors named "Gashema Pierre"

Background: Rwanda has made remarkable progress in scaling up HIV testing, treatment, and healthcare services. Recent data show that 95% of people living with HIV (PLWH) were aware of their status, 97.5% of them are on antiretroviral therapy (ART), and 98% of those who are on treatment have achieved viral suppression.

View Article and Find Full Text PDF

Sickle cell disease (SCD) is a prevalent inherited blood disorder, particularly affecting populations in Africa. This review examined the disease's burden, its diverse clinical presentations, and the challenges associated with its management in African settings. Africa bears a significant burden of SCD, with prevalence varying across countries and age groups.

View Article and Find Full Text PDF

The ongoing outbreak of Marburg virus disease in Rwanda marks the third largest historically, although it has shown the lowest fatality rate. Genomic analysis of samples from 18 cases identified a lineage with limited internal diversity, closely related to a 2014 Ugandan case. Our findings suggest that the Rwandan lineage diverged decades ago from a common ancestor shared with diversity sampled from bats in Uganda.

View Article and Find Full Text PDF

The Africa Centers for Disease Control and Prevention declared mpox a Public Health Emergency of Continental Security (PHECS) in Africa. African public health systems have moved to mobilize a response against a backdrop of inherent significant challenges. With this commentary, we discuss how lessons from past public health emergencies, particularly COVID-19 and Ebola outbreaks, have prepared the region for improved disease surveillance, rapid response strategies, and effective public health communication and how these lessons can be applied to the mpox response, emphasizing the importance of strong healthcare infrastructure, effective data sharing, community engagement, targeted interventions, and robust contact tracing.

View Article and Find Full Text PDF
Article Synopsis
  • In 2014, a significant mutation linked to artemisinin resistance, known as K13 561H, was first detected in Rwanda, making it crucial to monitor its spread.
  • Researchers utilized advanced blood preservation and pooled sequencing methods to assess the frequency of this mutation across multiple sites in Rwanda and neighboring countries from May 2022 to March 2023.
  • Results showed that K13 561H and 675V mutations were prevalent in Rwanda, with concerning additional mutations emerging, signaling threats to malaria treatment efficacy and control efforts in the region.
View Article and Find Full Text PDF

Objectives: In recent years, mpox, a zoonotic disease caused by the mpox virus, has transcended its primary association with Central and West Africa, emerging as a global public health concern. The virus poses a substantial threat, particularly, to vulnerable demographics such as young children and individuals with compromised immune systems. This critical literature review aimed to comprehensively evaluate the burden, risk factors, and current management strategies associated with mpox in Africa.

View Article and Find Full Text PDF

Antimicrobial resistance (AMR) is a significant global public health threat. This review presents the most recent in-depth review of the situation of the main AMR types in relation to the most commonly prescribed antibiotics in the World Health Organization (WHO) African Region. Underlying genes of resistance have been analyzed where possible.

View Article and Find Full Text PDF

Antimicrobial resistance (AMR) is a major public health threat linked to increased morbidity and mortality. It has the potential to return us to the pre-antibiotic era. Antimicrobial stewardship (AMS) programs are recognized as a key intervention to improve antimicrobial use and combat AMR.

View Article and Find Full Text PDF

Background: Emerging artemisinin partial resistance and diagnostic resistance are a threat to malaria control in Africa. Plasmodium falciparum kelch13 (k13) propeller-domain mutations that confer artemisinin partial resistance have emerged in Africa. k13-561H was initially described at a frequency of 7.

View Article and Find Full Text PDF
Article Synopsis
  • The first detection of the K13 artemisinin resistance mutation 561H occurred in Rwanda, highlighting the need for ongoing surveillance in East Africa as new mutations emerge.
  • A study involved collecting malaria-positive samples from 39 health facilities across Rwanda, Uganda, Tanzania, and the DRC, revealing high frequencies of mutations 561H and 675V in Rwanda, indicating significant resistance levels.
  • The presence of candidate mutations, alongside other known resistance markers, suggests a concerning trend of increasing drug resistance in the region, potentially threatening malaria treatment effectiveness.
View Article and Find Full Text PDF

Background: The COVID-19 pandemic has wrought a profound impact on mental health in Sub- Saharan Africa, exacerbating existing disparities and rendering individuals undergoing treatment particularly susceptible. This comprehensive critical review delves into the scope, nature, and extent of COVID-19 impact on mental health services in Sub- Saharan Africa, while concurrently elucidating pivotal lessons and exemplary practices learnt from periods of lockdown.

Methods: The methodology was guided by Jesson & Laccy's guide on how to conduct critical literature reviews.

View Article and Find Full Text PDF
Article Synopsis
  • Malaria is a significant health issue in sub-Saharan Africa, with asymptomatic infections contributing to ongoing transmission challenges, especially as non-falciparum malaria becomes more prevalent.
  • A study in Rwanda analyzed 4,596 individuals using quantitative PCR and found a 23.6% overall malaria infection rate, with asymptomatic falciparum malaria being widespread and low mixed-species infections common.
  • The findings highlight the need for ongoing monitoring of malaria species, emphasizing the connection between falciparum infections and factors like socio-economic status and location.
View Article and Find Full Text PDF

Background: Emerging artemisinin resistance and diagnostic resistance are a threat to malaria control in Africa. kelch13 (K13) propeller-domain mutations that confer artemisinin partial resistance have emerged in Africa. K13-561H was initially described at a frequency of 7.

View Article and Find Full Text PDF

Background: Considerable progress has been made globally in improving maternal and newborn babies' health. The COVID-19 pandemic has posed considerable challenges for countries to maintain the provision of high-quality, essential maternal and newborn healthcare services.

Methods: A rapid review was carried out on 20 March 2022 on postnatal care (PNC) services availability and utilization during the COVID-19 era in sub-Saharan Africa.

View Article and Find Full Text PDF

Viral enteric pathogens remain an important cause of diarrhoeal outbreaks among children in sub-Saharan Africa (SSA). Consequently, diarrhoeal illness remains a significant cause of morbidity and mortality in the under-fives in SSA. These outbreaks associated with viral pathogens tend to be seasonal and early warning systems for impending outbreaks could be very crucial for triggering preventive public health response and building public health resilience to deal with increased demand for medical services.

View Article and Find Full Text PDF

Introduction: there has been a global call to engage men in the fight against the HIV epidemic. Poor uptake of HIV testing services among men has been reported in most of sub-Saharan Africa where the HIV epidemic continues to be a major public health problem. HIV self-testing (HIVST) has potential to bridge the gap; however, there is a paucity of research evidence on oral-fluid-based HIVST experiences among men in Rwanda.

View Article and Find Full Text PDF

As with other countries globally, Rwanda has faced a recent outbreak of the coronavirus disease 2019 (COVID-19) against a backdrop of an HIV epidemic. At present, there is no successful cure or vaccine for both COVID-19 and HIV. People with underlying conditions, including HIV, are at increased risk of severe COVID-19 manifestations.

View Article and Find Full Text PDF